Ascentage Pharma’s Licensee UNITY Biotechnology Announces Milestone Reached in Clinical …,

The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate …, The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate …, Read More

Scroll to Top